A Phase 3 interventional study of Stereotactic Body Radiation and Transarterial Chemoembolization in Hepatocellular Carcinoma, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Phase 3, Interventional, and Treatment
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients.
A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.
HCC tends to remain within the liver and, therefore, cure with preserved liver function is possible.4 Treatments with relatively high success rates include surgical resection and liver transplantation. Surgical resection results in 5-year survival rates of approximately 60%-70%.4 Liver transplantation can cure both the cancer and underlying liver disease with 4-year survival for HCC within the Milan criteria (single HCC \<5 cm or ≤3 HCC \<3 cm) at 70%-85% after transplantation.5 Unfortunately, most patients are not resectable due to the extent of disease. Transarterial chemoembolization (TACE) has become the mainstay of treatment for unresectable HCC. 5,6 TACE is relatively safe due to the liver's unique vascular supply from the portal vein. HCC on the other hand, is supplied almost entirely by branches of the hepatic artery.7 In a randomized controlled trial for unresectable HCC not suitable for a curative intent, transarterial chemoembolisation or TACE were compared to conservative treatment.8 TACE induced objective responses (complete and partial response) that were sustained for at least 6 months in 35% of cases. Survival probabilities at 1 year and 2 years were 82% and 63% for TACE, significantly better than 63% and 27% obtained with conservative treatment. Overall survival at 1 and 2 years was also significantly better for the chemoembolization group 57% and 31% vs. 32% and 11%. However, many patients have large tumours and response rates to TACE decline rapidly with increasing size.9 TACE alone resulted in 2 year overall survivals of 42%, 0 and 0 for lesions 5-7cm, 8-10cm, and >10cm, respectively. Therefore, additional locally ablative treatments are being sought. In the same report, TACE plus radiation resulted in 2 year overall survivals of 63%, 50% and 17% for lesions 5-7cm, 8-10cm, and >10cm, respectively.9 External beam radiotherapy has long been considered to have a very limited role in the treatment of liver tumors. This has historically been because minimum dose required for local ablation exceeded the dose that would result in liver toxicity.10,11 The technical development of stereotactic body radiation therapy (SBRT), alone or in combination with TACE, renewed interest in radiation for HCC.12,13 For SBRT, advanced techniques are used to very accurately deliver a high total dose to the target in a small number of daily fractions while avoiding dose delivery to surrounding healthy structures. This research in HCC was done mainly by two groups, in Michigan and Stockholm, who demonstrated that the delivery of high doses of radiation to limited volumes of the liver had promising results in terms of local control and survival with acceptable toxicity.14,15 SBRT is offered as an ablative radical local treatment. In total as of 2015, eleven primary series reported on tumor response and survival of around 300 patients who have been treated with stereotactic body radiation therapy as primary therapy for HCC (Table A). The reported percentage of objective responses defined as complete and partial was ≥64% in 7 of 8 series. Median survival between 11.7 and 32 months has been observed. Toxicity, based on multiple case series trials, indicate that the treatment is considered safe. The most common CTC grade 3-4 toxicity was elevation of liver enzymes. 16-19 For unresectable cases, both TACE and SBRT have been used safely and with good efficacy as separate treatments. Particularly for larger lesions that are more commonly seen in London, the outcome remains suboptimal compared to surgery. Combined treatment case series have shown dramatic results (Table B), but there has not been any randomized trial to compare the value of combining the two modalities. Therefore, a clinical study comparing SBRT and SBRT+TACE will be significant as it addresses a common problem in one of the two most deadly cancers.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 128 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 309 studies on the registry; 126 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pretreatment Evaluations Required for Eligibility:
Exclusion Criteria:
Transarterial Chemoembolization (TACE)
Drug: Transarterial Chemoembolization
Stereotactic Body Radiation Therapy (SBRT)
Radiation: Stereotactic Body Radiation
For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
Also known as: TACE
Overall Survival
Overall Survival-number of patients alive censored for deaths by any cause
Time frame: At 2 years from start of treatment
Time to Intrahepatic Progression
This will be measured using the modified RECIST (Response evaluation criteria in solid tumors) criteria
Time frame: Pre-treatment, at 1 month and 3 month follow-up, and at follow-up every 3 months up to 2 years
Measurement of Response Rate
Modified RECIST (Response Evaluation Criteria in Solid Tumors) criteria
Time frame: The sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference by which to characterize the objective tumor.
Local Failure
Within 1 cm from the original tumor volume
Time frame: 5 years
Extrahepatic failure
This will be defined as any lesion found to be new or progressing outside the hepatic organ.
Time frame: Pre-treatment, at 1 month and 3 month follow-up, and at follow-up every 3 months up to 2 years
Time to intrahepatic progression
This will be measured using the modified RECIST (Response evaluation criteria in solid tumors) criteria
Time frame: Pre-treatment, at 1 month and 3 month follow-up, and at follow-up every 3 months up to 2 years
Radiation Therapy Overall Toxicity Assessment
CTC V4.0 (Common Terminology Criteria version 4.0)
Time frame: Weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years
Radiation Therapy Classic Radiation Toxicity Assessment
Classic RILD (Radiation-induced liver disease)
Time frame: Weekly during treatment , 1 and 3 month follow-up, and every 3 months thereafter up to 2 years
Radiation Therapy Non-Classic Toxicity Assessment
Non-classic RILD (Radiation-induced liver disease)
Time frame: Weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years
Radiation Therapy Toxicity Assessment
Measured using Child-Pugh score to indicate the severity of toxicity. Five variables are considered: presence of ascites, encephalopathy, serum levels of albumin, total bilirubin and prolongation of the clotting time. Each of these variables is assigned a score between 1 and 3 according to its severity or degree of abnormality. The sum of the five scores is used to assign a "Child-Pugh grade" of A, B or C to the patient's clinical condition at that point in time. Grade A indicates a well-functioning liver, Grade B indicates significant functional compromise, Grade C indicates decompensation of the liver.
Time frame: Patients will be assessed at least once during radiation therapy for toxicity
Change in Health related Quality of Life (QOL)
Measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ H\&N35 (Quality of Life Questionnaire Head \& Neck). According to the EORTC scoring guidelines All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Pre-Treatment, weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter
Overall Quality of Life (QOL)
QLQC30 (Quality of Life Questionnaire version 3)
Time frame: Pre-Treatment, weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years
Liver Related Quality of Life (QOL)
FACT-L (Functional Assessment of Cancer Therapy-Lung)
Time frame: Pre-Treatment, weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years
Cost-benefit
A cost benefit analysis will be used to evaluate the total anticipated cost of the project and compare it to the total expected benefits.
Time frame: Through study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's